Regulation of cancer cell survival by BCL2 family members upon prolonged mitotic arrest: opportunities for anticancer therapy

Anticancer Research

Volumn 32, Issue 10, 2012, Pages 4225-4233

  Barillé Nion, Sophie ^a   Bah, Nourdine ^a   V́equaud, Eloïse ^a   Juin, Philippe ^a,b  

^a UNIVERSITÉ DE NANTES   (France)

^b ICO René Gauducheau ^*  (France)

Author keywords

Anti mitotic agents; BCL2 family; BH3 mimetics; Cell death; mitotic arrest; Polyploidy; Review

Indexed keywords

4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; ANTIMITOTIC AGENT; ANTINEOPLASTIC AGENT; APC PROTEIN; AURORA A KINASE; BH3 PROTEIN; BUB1 RELATED PROTEIN; CASPASE 9; CYCLIN B1; CYCLIN DEPENDENT KINASE 1; DOCETAXEL; NAVITOCLAX; PACLITAXEL; PHOSPHOPROTEIN PHOSPHATASE 1; PHOSPHOPROTEIN PHOSPHATASE 2A; PROTEIN BAK; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN P53; TAXANE DERIVATIVE; UBIQUITIN PROTEIN LIGASE; UBIQUITIN PROTEIN LIGASE E3; X LINKED INHIBITOR OF APOPTOSIS;

APOPTOSIS; BINDING AFFINITY; BREAST TUMOR; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER RESISTANCE; CELL ASSAY; CELL DEATH; CELL FATE; CELL SURVIVAL; CLINICAL TRIAL (TOPIC); CRYSTAL STRUCTURE; CYTOKINESIS; DRUG CYTOTOXICITY; DRUG PROTEIN BINDING; DRUG SENSITIZATION; DRUG TARGETING; ENZYME ACTIVITY; GENE EXPRESSION; HUMAN; M PHASE CELL CYCLE CHECKPOINT; MICROTUBULE; MITOSIS INDEX; MITOSIS INHIBITION; NEUROTOXICITY; NONHUMAN; ONCOGENE C JUN; ONCOGENE C MYC; POLYPLOIDY; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; REVIEW; SENESCENCE; SEQUENCE HOMOLOGY; SIGNAL TRANSDUCTION; TREATMENT RESPONSE; TUMOR MICROENVIRONMENT; UBIQUITINATION;

ANIMALS; ANTIMITOTIC AGENTS; APOPTOSIS; CELL CYCLE CHECKPOINTS; CELL SURVIVAL; HUMANS; MICE; MITOSIS; NEOPLASMS; PROTO-ONCOGENE PROTEINS C-BCL-2;

EID: 84867762957     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (54)

1. Gallenne T, Gautier F, Oliver L, Hervouet E, Noël B, Hickman JA, Geneste O, Cartron P-F, Vallette FM, Manon S and Juin P: BAX activation by the BH3-only protein PUMA promotes cell dependence on antiapoptotic BCL2 family members. J Cell Biol 185: 279-290, 2009.
2. Chonghaile TN and Letai A: Mimicking the BH3 domain to kill cancer cells. Oncogene 27: S149-S157, 2009.
3. Youle RJ and Strasser A: The BCL2 protein family: Opposing activities that mediate cell death. Nat Rev Mol Cell Biol 9: 47-59, 2008.
4. Campone M, Noël B, Couriaud C, Grau M, Guillemin Y, Gautier F, Gouraud W, Charbonnel C, Campion L, Jézéquel P, Braun F, Barré B, Coqueret O, Barillé-Nion S and Juin P: c-MYC dependent expression of proapoptotic BIM renders HER2-overexpressing breast cancer cells dependent on antiapoptotic MCL1. Mol Cancer 10: 110-124, 2011.
5. Gascoigne KE and Taylor SS: Cancer cells display profound intra- and interline variation following prolonged exposure to antimitotic drugs. Cancer Cell 14: 111-122, 2008.
6. Flores M, Castilla C, Ávila R, Ruiz-Borrego M, Sáez C, Japón M: Paclitaxel sensitivity of breast cancer cells requires efficient mitotic arrest and disruption of BCLXL/BAK interaction. Breast Cancer Res Treat 133: 917-928, 2012.
7. Kutuk O and Letai A: Alteration of the mitochondrial apoptotic pathway is key to acquired paclitaxel resistance and can be reversed by ABT-737. Cancer Res 68: 7985-7994, 2008.
8. Weaver BAA and Cleveland DW: Decoding the links between mitosis, cancer, and chemotherapy: The mitotic checkpoint, adaptation, and cell death. Cancer Cell 8: 7-12, 2005. (Pubitemid 40991810)
9. Harley ME, Allan LA, Sanderson HS, Clarke PR: Phosphorylation of MCL1 by CDK1-cyclin B1 initiates its cdc20-dependent destruction during mitotic arrest. EMBO J 29: 2407-2420, 2010.
10. Wertz IE, Kusam S, Lam C, Okamoto T, Sandoval W, Anderson DJ, Helgason E, Ernst JA, Eby M, Liu J, Belmont LD, Kaminker JS, O'Rourke KM, Pujara K, Kohli PB, Johnson AR, Chiu ML, Lill JR, Jackson PK, Fairbrother WJ, Seshagiri S, Ludlam MJC, Leong KG, Dueber EC, Maecker H, Huang DCS and Dixit VM: Sensitivity to antitubulin chemotherapeutics is regulated by MCL1 and FBW7. Nature 471: 110-114, 2011.
11. Shi J, Zhou Y, Huang H-C, Mitchison TJ: Navitoclax (ABT-263) accelerates apoptosis during drug-induced mitotic arrest by antagonizing BCLXL. Cancer Res 71: 4518-4526, 2011.
12. Terrano DT, Upreti M and Chambers TC: Cyclin-dependent kinase 1-mediated BCLXL/BCL2 phosphorylation acts as a functional link coupling mitotic arrest and apoptosis. Mol Cell Biol 30: 640-656, 2010.
13. Barboule N, Truchet I and Valette A: Localization of phosphorylated forms of BCL2 in mitosis: co-localization with Ki-67 and nucleolin in nuclear structures and on mitotic chromosomes. Cell Cycle 4: 590-596, 2005. (Pubitemid 41359788)
14. Du L, Lyle CS and Chambers TC: Characterization of vinblastine-induced BCLXL and BCL2 phosphorylation: evidence for a novel protein kinase and a coordinated phosphorylation/dephosphorylation cycle associated with apoptosis induction. Oncogene 24: 107-117, 2005. (Pubitemid 40143870)
15. Upreti M, Galitovskaya EN, Chu R, Tackett AJ, Terrano DT, Granell S and Chambers TC: Identification of the major phosphorylation site in BCLXL induced by microtubule inhibitors and analysis of its functional significance. J Biol Chem 283: 35517-35525, 2008.
16. Blagosklonny MV: Unwinding the loop of BCL2 phosphorylation. Leukemia 15: 869-874, 2001.
17. Ruvolo PP, Deng X and May WS: Phosphorylation of Bcl2 and regulation of apoptosis. Leukemia 15: 515-522, 2001. (Pubitemid 32266720)
18. Basu A and Haldar S: Identification of a novel BCLXL phosphorylation site regulating the sensitivity of taxol- or 2-methoxyestradiol-induced apoptosis. FEBS Letters 538: 41-47, 2003. (Pubitemid 36287422)
19. Tamura Y, Simizu S, Muroi M, Takagi S, Kawatani M, Watanabe N and Osada H: Polo-like kinase 1 phosphorylates and regulates Bcl-x(L) during pironetin-induced apoptosis. Oncogene 28: 107-116, 2009.
20. Wang J, Beauchemin M and Bertrand R: BCLXL phosphorylation at Ser49 by polokinase 3 during cell cycle progression and checkpoints. Cell Signal 23: 2030-2038, 2011.
21. Allan LA and Clarke PR: Phosphorylation of caspase-9 by CDK1/Cyclin B1 protects mitotic cells against apoptosis. Mol Cell 26: 301-310, 2007. (Pubitemid 46617338)
22. Barrett R, Osborne TP and Wheatley SP: Phosphorylation of survivin at threonine 34 inhibits its mitotic function and enhances its cytoprotective activity. Cell Cycle 8: 278-283, 2009.
23. Brichese L and Valette A: PP1 phosphatase is involved in BCL2 dephosphorylation after prolonged mitotic arrest induced by paclitaxel. Biochem Biophys Res Comm 294: 504-508, 2002. (Pubitemid 34694122)
24. Schwickart M, Huang X, Lill JR, Liu J, Ferrando R, French DM, Maecker H, O'Rourke K, Bazan F, Eastham-Anderson J, Yue P, Dornan D, Huang DCS and Dixit VM: Deubiquitinase USP9X stabilizes MCL1 and promotes tumour cell survival. Nature 463: 103-107, 2010.
25. Sherrill KW, Byrd MP, Van Eden ME and Lloyd RE: BCL2 translation is mediated via internal ribosome entry during cell stress. J Biol Chem 279: 29066-29074, 2004. (Pubitemid 38915777)
26. Marash L, Liberman N, Henis-Korenblit S, Sivan G, Reem E, Elroy-Stein O and Kimchi A: DAP5 promotes cap-independent translation of BCL2 and CDK1 to facilitate cell survival during mitosis. Mol Cell 30: 447-459, 2008.
27. Holcik M, Graber T, Lewis SM, Lefebvre CA, Lacasse E and Baird S: Spurious splicing within the XIAP 5′ UTR occurs in the Rluc/Fluc but not the beta-gal/CAT bicistronic reporter system. RNA 11: 1605-1609, 2005. (Pubitemid 41505533)
28. Moore MJ, Wang Q, Kennedy CJ and Silver PA: An alternative splicing network links cell-cycle control to apoptosis. Cell 142: 625-636, 2010.
29. Toh WH, Nam SY and Sabapathy K: An essential role for p73 in regulating mitotic cell death. Cell Death Differ 17: 787-800, 2010.
30. Niikura Y, Dixit A, Scott R, Perkins G and Kitagawa K: BUB1 mediation of caspase-independent mitotic death determines cell fate. J Cell Biol 178: 283-296, 2007. (Pubitemid 47076464)
31. Huang HC, Mitchison TJ and Shi J: Stochastic competition between mechanistically independent slippage and death pathways determines cell fate during mitotic arrest. PLoS ONE 5: e15724, 2010.
32. Lee K, Kenny AE and Rieder CL: Caspase activity is not required for the mitotic checkpoint or mitotic slippage in human cells. Mol Biol Cell 22: 2470-2479, 2011.
33. Kim M, Murphy K, Liu F, Parker SE, Dowling ML, Baff W and Kao GD: Caspase-mediated specific cleavage of BubR1 is a determinant of mitotic progression. Mol Cell Biol 25: 9232-9248, 2005. (Pubitemid 41507826)
34. Schmitt E, Beauchemin M and Bertrand R: Nuclear colocalization and interaction between BCLXL and cdk1(cdc2) during G2/|M cell-cycle checkpoint. Oncogene 26: 5851-5865, 2007.
35. Orth JD, Loewer A, Lahav G and Mitchison TJ: Prolonged mitotic arrest triggers partial activation of apoptosis, resulting in DNA damage and p53 induction. Mol Biol Cell 23: 567-576, 2012.
36. Vitale I, Galluzzi L, Senovilla L, Criollo A, Jemaà M, Castedo M and Kroemer G: Illicit survival of cancer cells during polyploidization and depolyploidization. Cell Death Differ 18: 1403-1413, 2011.
37. Castedo M, Coquelle A, Vivet S, Vitale I, Kauffmann A, Dessen P, Pequignot MO, Casares N, Valent A, Mouhamad S, Schmitt E, Modjtahedi N, Vainchenker W, Zitvogel L, Lazar V, Garrido C and Kroemer G: Apoptosis regulation in tetraploid cancer cells. EMBO J 25: 2584-2595, 2006. (Pubitemid 44012240)
38. Storchova Z, Kuffer C: The consequences of tetraploidy and aneuploidy. J Cell Sci 121: 3859-3866, 2008.
39. Shah OJ, Lin X, Li L, Huang X, Li J, Anderson MG, Tang H, Rodriguez LE, Warder SE, McLoughlin S, Chen J, Palma J, Glaser KB, Donawho CK, Fesik SW and Shen Y: BCLXL represents a druggable molecular vulnerability during aurora B inhibitor-mediated polyploidization. Proc Natl Acad Sci USA 107: 12634-12639, 2010.
40. Huang H-C, Shi J, Orth JD and Mitchison TJ: Evidence that mitotic exit is a better cancer therapeutic target than spindle assembly. Cancer Cell 16: 347-358, 2009.
41. Manchado E, Guillamot M, de Cárcer G, Eguren M, Trickey M, García-Higuera I, Moreno S, Yamano H, Cañamero M and Malumbres M: Targeting mitotic exit leads to tumor regression in vivo: Modulation by CDK1, Mastl, and the PP2A/B55α,aδ Phosphatase. Cancer Cell 18: 641-654, 2010.
42. Zeng X, Sigoillot F, Gaur S, Choi S, Pfaff KL, Oh D-C, Hathaway N, Dimova N, Cuny GD and King RW: Pharmacologic inhibition of the anaphase-promoting complex induces a spindle checkpoint-dependent mitotic arrest in the absence of spindle damage. Cancer Cell 18: 382-395, 2010.
43. Marcus AI, Peters U, Thomas SL, Garrett S, Zelnak A, Kapoor TM and Giannakakou P: Mitotic kinesin inhibitors induce mitotic arrest and cell death in taxol-resistant and -sensitive Cancer Cells. J Biol Chem 280: 11569-11577, 2005. (Pubitemid 40418469)
44. Komlodi-Pasztor E, Sackett DL and Fojo AT: Inhibitors targeting mitosis: Tales of how great drugs against a promising target were brought down by a flawed rationale. Clin Cancer Res 18: 51-63, 2012.
45. Vogler M, Weber K, Dinsdale D, Schmitz I, Schulze-Osthoff K, Dyer MJS and Cohen GM: Different forms of cell death induced by putative BCL2 inhibitors. Cell Death Differ 16: 1030-1039, 2009.
46. Konopleva M, Contractor R, Tsao T, Samudio I, Ruvolo PP, Kitada S, Deng X, Zhai D, Shi Y-X, Sneed T, Verhaegen M, Soengas M, Ruvolo VR, McQueen T, Schober WD, Watt JC, Jiffar T, Ling X, Marini FC, Harris D, Dietrich M, Estrov Z, McCubrey J, May WS, Reed JC and Andreeff M: Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. Cancer Cell 10: 375-388, 2006. (Pubitemid 44693472)
47. van Delft MF, Wei AH, Mason KD, Vandenberg CJ, Chen L, Czabotar PE, Willis SN, Scott CL, Day CL, Cory S, Adams JM, Roberts AW and Huang DCS: The BH3 mimetic ABT-737 targets selective BCL2 proteins and efficiently induces apoptosis via BAK/BAX if MCL1 is neutralized. Cancer Cell 10: 389-399, 2006. (Pubitemid 44711953)
48. Tan N, Malek M, Zha J, Yue P, Kassees R, Berry L, Fairbrother WJ, Sampath D and Belmont LD: Navitoclax enhances the efficacy of taxanes in non-small cell lung cancer models. Clin Cancer Res 17: 1394-1404, 2011.
49. Oakes SR, Vaillant F, Lim E, Lee L, Breslin K, Feleppa F, Deb S, Ritchie ME, Takano E, Ward T, Fox SB, Generali D, Smyth GK, Strasser A, Huang DCS, Visvader JE and Lindeman GJ: Sensitization of BCL2-expressing breast tumors to chemotherapy by the BH3 mimetic ABT-737. Proc Natl Acad Sci USA 109: 2766-2771, 2012.
50. Symmans WF, Volm MD, Shapiro RL, Perkins AB, Kim AY, Demaria S, Yee HT, McMullen H, Oratz R, Klein P, Formenti SC and Muggia F: Paclitaxel-induced apoptosis and mitotic arrest assessed by serial fine-needle aspiration: Implications for early prediction of breast cancer response to neoadjuvant treatment. Clin Cancer Res 6: 4610-4617, 2000. (Pubitemid 32110395)
51. Liedtke C, Wang J, Tordai A, Symmans WF, Hortobagyi GN, Kiesel L, Hess K, Baggerly KA, Coombes KR and Pusztai L: Clinical evaluation of chemotherapy response predictors developed from breast cancer cell lines. Breast Cancer Res Treat 121: 301-309, 2010.
52. Kadra G, Finetti P, Toiron Y, Viens P, Birnbaum D, Borg J-P, Bertucci F and Gonçalves A: Gene expression profiling of breast tumor cell lines to predict for therapeutic response to microtubule-stabilizing agents. Breast Cancer Res Treat 132: 1035-1047, 2012.
53. Séveno C, Loussouarn D, Bréchet S, Campone M, Juin P and Barillé-Nion S: γ-Secretase inhibition promotes cell death, NOXA up-regulation, and sensitization to BH3 mimetic ABT-737 in human breast cancer cells. Breast Cancer Res 14: R96 [Epub ahead of print], 2012.
54. Chonghaile TN, Sarosiek KA, Vo T-T, Ryan JA, Tammareddi A, Moore VDG, Deng J, Anderson KC, Richardson P, Tai Y-T, Mitsiades CS, Matulonis UA, Drapkin R, Stone R, DeAngelo DJ, McConkey DJ, Sallan SE, Silverman L, Hirsch MS, Carrasco DR and Letai A: Pretreatment mitochondrial priming correlates with clinical response to cytotoxic chemotherapy. Science 334: 1129-1133, 2011.